Alt-protein
-
DATABASE (44)
-
ARTICLES (132)
Lever VC was founded in 2018 by Nick Cooney, an early investor of Beyond Meat and Memphis Meats. He is also the co-founder of Good Food Institute. Lever has currently invested in 14 startups from the US, Europe, Asia and Latin America.Focused on investments in early-stage alternative protein companies, the firm announced the first close of its Lever VC Fund I in August 2020, with its fourth close at $46m in April 2021. The final close will be completed by June 2021. Investors in the fund include NFL and NBA athletes, British nobility, food businesses, alt-protein companies and family offices as limited partners.In June 2020, Lever launched a $28m joint investment fund and accelerator to invest in Chinese plant-based and cell-cultivated meat and dairy companies. The Lever China Alternative Protein Fund will invest RMB 40m in alt-protein companies in mainland China over the next four years.
Lever VC was founded in 2018 by Nick Cooney, an early investor of Beyond Meat and Memphis Meats. He is also the co-founder of Good Food Institute. Lever has currently invested in 14 startups from the US, Europe, Asia and Latin America.Focused on investments in early-stage alternative protein companies, the firm announced the first close of its Lever VC Fund I in August 2020, with its fourth close at $46m in April 2021. The final close will be completed by June 2021. Investors in the fund include NFL and NBA athletes, British nobility, food businesses, alt-protein companies and family offices as limited partners.In June 2020, Lever launched a $28m joint investment fund and accelerator to invest in Chinese plant-based and cell-cultivated meat and dairy companies. The Lever China Alternative Protein Fund will invest RMB 40m in alt-protein companies in mainland China over the next four years.
With a 55-tone capacity to produce fungi-based proteins annually, Mycorena’s Gothenburg facility will showcase its mycoprotein R&D and spur commercial expansion across Europe.
With a 55-tone capacity to produce fungi-based proteins annually, Mycorena’s Gothenburg facility will showcase its mycoprotein R&D and spur commercial expansion across Europe.
Bånt AB is the investment vehicle of Karl Sverker Forsén based in Luleå, a coastal city in Swedish Lapland. In May 2020, the Swedish family office invested in a Gothenburg startup Mycorena, a biotech that produces mycoproteins through fermentation. The fungi-based protein can be used as an alt-protein ingredient instead of traditional plant-based food components.
Bånt AB is the investment vehicle of Karl Sverker Forsén based in Luleå, a coastal city in Swedish Lapland. In May 2020, the Swedish family office invested in a Gothenburg startup Mycorena, a biotech that produces mycoproteins through fermentation. The fungi-based protein can be used as an alt-protein ingredient instead of traditional plant-based food components.
WWF-backed biotech Oceanium has developed a biorefinery that transforms seaweed into alt-proteins and compostable packaging that will soon be launched commercially.
WWF-backed biotech Oceanium has developed a biorefinery that transforms seaweed into alt-proteins and compostable packaging that will soon be launched commercially.
E²JDJ was founded in New Orleans in 2020 with an agtech and foodtech focus, including in the areas of cellular agriculture and synthetic biology. It has six startups in its portfolio and makes diverse investments. Its most recent disclosed investment was in the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions.
E²JDJ was founded in New Orleans in 2020 with an agtech and foodtech focus, including in the areas of cellular agriculture and synthetic biology. It has six startups in its portfolio and makes diverse investments. Its most recent disclosed investment was in the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions.
CEO and founder of Mycorena
Ramkumar Nair graduated in biotechnology at the Cochin University of Science and Technology in Kerala before going to Sweden for postgrad studies in 2013.During his PhD in industrial biotechnology at the University of Borås, he embarked on a research project to create fungi-based proteins from discarded sidestreams generated by food producers. After extensive research in 2017, he founded Mycorena in Gothenburg to produce mycoproteins using fermentation technology.The startup’s first commercial product, Promyc, is now being sold to global food companies as a more sustainable and nutritional alt-protein compared to traditional plant-based proteins.
Ramkumar Nair graduated in biotechnology at the Cochin University of Science and Technology in Kerala before going to Sweden for postgrad studies in 2013.During his PhD in industrial biotechnology at the University of Borås, he embarked on a research project to create fungi-based proteins from discarded sidestreams generated by food producers. After extensive research in 2017, he founded Mycorena in Gothenburg to produce mycoproteins using fermentation technology.The startup’s first commercial product, Promyc, is now being sold to global food companies as a more sustainable and nutritional alt-protein compared to traditional plant-based proteins.
CEO and founder of Plantruption
Jennifer O'Brien qualified as a financial advisor at University College Dublin in 2010. She started her banking career in 2007 at AIB where she spent six years working with SMEs and investments. In 2013, she joined KBC Bank Ireland as a restructures executive and went on to work as an asset manager at Link Asset Services in 2016. O’Brien also worked in asset management for two years at O’Dwyer Real Estate Management while completing an MBA at Trinity College Dublin. She left the realty company in 2019 to realize her dream to create alt-protein seafood using locally sourced seaweed.
Jennifer O'Brien qualified as a financial advisor at University College Dublin in 2010. She started her banking career in 2007 at AIB where she spent six years working with SMEs and investments. In 2013, she joined KBC Bank Ireland as a restructures executive and went on to work as an asset manager at Link Asset Services in 2016. O’Brien also worked in asset management for two years at O’Dwyer Real Estate Management while completing an MBA at Trinity College Dublin. She left the realty company in 2019 to realize her dream to create alt-protein seafood using locally sourced seaweed.
Founded in 2017 in Hong Kong, Happiness Capital invests in seed to growth stage companies in the US, Europe, Israel, and China, with a focus on issues affecting global happiness within the areas of citizen trust, food, health, climate change, and reduced inequalities. It hosts its own annual contest, the Super Happiness Challenge , a global open innovation contest to fund individuals and startups with ideas and new products or services that tapped into unmet needs to achieve happiness, with a possible $1m in total investment on offer. The VC currently has 37 startups in its portfolio, around half of which are in foodtech and agtech. Its most recent investments include leading the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions, and co-leading the $29m February 2021 Series A round of Israeli 3D printed alt-meat startup Redefine Meat.
Founded in 2017 in Hong Kong, Happiness Capital invests in seed to growth stage companies in the US, Europe, Israel, and China, with a focus on issues affecting global happiness within the areas of citizen trust, food, health, climate change, and reduced inequalities. It hosts its own annual contest, the Super Happiness Challenge , a global open innovation contest to fund individuals and startups with ideas and new products or services that tapped into unmet needs to achieve happiness, with a possible $1m in total investment on offer. The VC currently has 37 startups in its portfolio, around half of which are in foodtech and agtech. Its most recent investments include leading the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions, and co-leading the $29m February 2021 Series A round of Israeli 3D printed alt-meat startup Redefine Meat.
Based in London, CPT Capital is the venture arm of private equity pioneer Jeremy Coller's private family office. Coller is the founder of Europe’s first private equity for secondaries in 1990. The British philanthropist has also established several business schools and the Jeremy Coller Foundation that aims to eliminate factory farming. In 2017, CPT Capital was founded to disrupt the food industry with investments in the alt-protein sector to create the “future of food and materials” like plant-based, recombinant and cell-cultured proteins.
Based in London, CPT Capital is the venture arm of private equity pioneer Jeremy Coller's private family office. Coller is the founder of Europe’s first private equity for secondaries in 1990. The British philanthropist has also established several business schools and the Jeremy Coller Foundation that aims to eliminate factory farming. In 2017, CPT Capital was founded to disrupt the food industry with investments in the alt-protein sector to create the “future of food and materials” like plant-based, recombinant and cell-cultured proteins.
Mitchell Presser is a New York-based lawyer. He is currently co-chair of global law service Morrison & Foerster’s Global Corporate Department and a partner in the firm’s M&A and Private Equity group, advising on agriculture, amongst other areas. He previously was a founding partner of Paine Schwartz, a US-based $1.2 bn private equity firm specializing in sustainable food chain investing from 2006 to 2014. His sole disclosed angel investment to date was an undisclosed sum in the pre-seed funding of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions,
Mitchell Presser is a New York-based lawyer. He is currently co-chair of global law service Morrison & Foerster’s Global Corporate Department and a partner in the firm’s M&A and Private Equity group, advising on agriculture, amongst other areas. He previously was a founding partner of Paine Schwartz, a US-based $1.2 bn private equity firm specializing in sustainable food chain investing from 2006 to 2014. His sole disclosed angel investment to date was an undisclosed sum in the pre-seed funding of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions,
Chairman of the Board, co-founder, co-inventor of NovoNutrients
Russell J. Howard has been co-founder and chairman of the board at NovoNutrients, a San Francisco biotech manufacturer of alt-protein produced using fermentation and CO2, and the research company Oakbio, since the latter’s foundation in 2009. During this period, for a year, Howard also worked as head of commercial strategy at Genome.One, a genetics startup. Howard is also on the board of executives of two Australian pharma companies, Immutep and NeuClone. Previously, between 1997 and 2009, he was CEO at California-based Maxygen, dedicated to the commercialization of molecular breeding and gene shuffling in protein. The year before that, Howard was president and scientific director at global pharma giant GSK in Santa Clara, and between 1994 and 1996, he held the same position at AFFYMAX Research Institute, working on new drugs research. Howard also held long-term research positions, heading up the laboratory at Palo Alto’s DNAX Research Institute of Molecular & Cellular Biology for six years, and earlier spent nine years at Bethesda’s National Institute of Allergy and Infectious Diseases (NIAID) working on identifying new malarial pathogens. The doctor of biochemistry from the University of Melbourne has over 140 peer-reviewed publications. Following his studies, Howard spent three years undertaking postdoctoral research at Australia’s WEHI (formerly the Walter and Eliza Hall Institute of Medical Research).
Russell J. Howard has been co-founder and chairman of the board at NovoNutrients, a San Francisco biotech manufacturer of alt-protein produced using fermentation and CO2, and the research company Oakbio, since the latter’s foundation in 2009. During this period, for a year, Howard also worked as head of commercial strategy at Genome.One, a genetics startup. Howard is also on the board of executives of two Australian pharma companies, Immutep and NeuClone. Previously, between 1997 and 2009, he was CEO at California-based Maxygen, dedicated to the commercialization of molecular breeding and gene shuffling in protein. The year before that, Howard was president and scientific director at global pharma giant GSK in Santa Clara, and between 1994 and 1996, he held the same position at AFFYMAX Research Institute, working on new drugs research. Howard also held long-term research positions, heading up the laboratory at Palo Alto’s DNAX Research Institute of Molecular & Cellular Biology for six years, and earlier spent nine years at Bethesda’s National Institute of Allergy and Infectious Diseases (NIAID) working on identifying new malarial pathogens. The doctor of biochemistry from the University of Melbourne has over 140 peer-reviewed publications. Following his studies, Howard spent three years undertaking postdoctoral research at Australia’s WEHI (formerly the Walter and Eliza Hall Institute of Medical Research).
San Francisco-based BOND is a spinoff of Kleiner Perkins and its original digital growth fund. BOND was launched in 2019, investing across market segments and geographies. To date, it has raised two funds totaling $3.3bn and currently has 32 portfolio companies. Its recent investments include Portuguese home physiotherapy tech SWORD, the world’s fastest-growing musculoskeletal solution, in June 2021 in a $85m Series C funding round; and co-leading the July 2021 $50m Series B round of US fungi-based alt-protein startup Meati Foods.
San Francisco-based BOND is a spinoff of Kleiner Perkins and its original digital growth fund. BOND was launched in 2019, investing across market segments and geographies. To date, it has raised two funds totaling $3.3bn and currently has 32 portfolio companies. Its recent investments include Portuguese home physiotherapy tech SWORD, the world’s fastest-growing musculoskeletal solution, in June 2021 in a $85m Series C funding round; and co-leading the July 2021 $50m Series B round of US fungi-based alt-protein startup Meati Foods.
Marinya Capital is the family office ofJohn B Fairfax from the Australian Fairfax family, who originally established Fairfax Media, a large media company. Marinya largely invests in property and agricultural businesses but has also made at least two investments in tech startups and in an Australian VC. Its most recent disclosed investments were in the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein using fermentation and CO2 and other emissions, and in the $55m Series B round of Australia’s premier plant-based brand v2food in 2020.
Marinya Capital is the family office ofJohn B Fairfax from the Australian Fairfax family, who originally established Fairfax Media, a large media company. Marinya largely invests in property and agricultural businesses but has also made at least two investments in tech startups and in an Australian VC. Its most recent disclosed investments were in the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein using fermentation and CO2 and other emissions, and in the $55m Series B round of Australia’s premier plant-based brand v2food in 2020.
Nutrinsect’s cricket flour is a 100% organic alternative protein containing twice the protein of soy, with an all-purpose natural fertilizer as its byproduct.
Nutrinsect’s cricket flour is a 100% organic alternative protein containing twice the protein of soy, with an all-purpose natural fertilizer as its byproduct.
Co-founder of Xampla
Tuomas Knowles is co-founder of Britain’s Xampla, producer of plant-based biodegradable plastics made from protein, which was founded in 2018 based on his team’s pioneering research. Knowles is a professor of physical chemistry and biophysics at Cambridge University, where he has worked since 2010 and manages the Knowles Lab which focuses on researching protein self-assembly underlying neurodegenerative disorders like Alzheimer's and Parkinson's disease. Knowles holds a PhD in Biophysics from the University of Cambridge and a degree in physics from ETH Zurich, a science and technology university.
Tuomas Knowles is co-founder of Britain’s Xampla, producer of plant-based biodegradable plastics made from protein, which was founded in 2018 based on his team’s pioneering research. Knowles is a professor of physical chemistry and biophysics at Cambridge University, where he has worked since 2010 and manages the Knowles Lab which focuses on researching protein self-assembly underlying neurodegenerative disorders like Alzheimer's and Parkinson's disease. Knowles holds a PhD in Biophysics from the University of Cambridge and a degree in physics from ETH Zurich, a science and technology university.
Doinn: Impeccable housekeeping for lucrative holiday rentals
With its tech tools, better working conditions and 5-star ratings, the Portuguese startup now wants to expand to Southeast Asia and get Series A funding
Bayer Growth Ventures' Paimun Amini: Invest in tech for smarter, more sustainable farming
Corporate venture capital showed up in abundance at Smart Agrifood Malaga, where CompassList spoke with Paimun Amini, Director of Venture Investments for Bayer Growth Ventures (BGV)
Future Food Asia: Covid-19 sparked dramatic shifts in agriculture in China and India
Key Chinese players from e-commerce giant Pinduoduo and and agritech VC Omnivore share their insights at last week’s agrifood conference by ID Capital
Cocuus: Industrial-scale solutions to design and print food
This Spanish startup is pioneering industrial-scale 3D food printing using inkjet and laser technology that prints up to 30 times faster with eye-catching food designs
Harnessing its innovative startups, Portugal builds a better cleantech ecosystem
With help from government and private-sector initiatives, Portuguese cleantech startups are playing an ever-increasing role in helping the country meet its energy challenges while cutting harmful greenhouse gases
Spotahome CTO: Room for more real estate disruption, beyond rentals
Bryan McEire, CTO and co-founder of the Spanish proptech startup, details their expansion plans this year and more, in a wide-ranging interview
Smart Agrifood Summit 2019 big winner Agri Marketplace makes fair trade easy
Winner of Best Startup and Best Innovative Agrifood Startup, Agri Marketplace presented its fast, transparent and interconnected crop trading platform at Málaga Smart Agrifood Summit 2019
ChainGo is using Ethereum to boost the €2.7-trillion logistics sector
Co-founders Andres Garrido and Jordan Sorensen are using Ethereum to help the unwieldy ocean freight industry to become more efficient, transparent and secure through the blockchain's decentralized system.
Spanish business angel Carlos Blanco is betting big bucks on local startups
The serial investor learnt the tricks of the trade early at Barcelona’s flea market
IONIC AI: Human-centric technology that enhances mobile phone performance
Giving new life to old mobile phones and upgrading cheaper ones, IONIC AI's tech also keeps gamers' phones cool for longer usage
Wahyoo wins seed funding in push to upgrade Indonesia's street food sector
It's launching a B2C app and an integrated POS system in 2019 to boost street food sales and hawkers' productivity, CEO Peter Shearer tells CompassList
Choose from over 10,000 mental health therapists at Yidianling
Startup's 24/7 services will include AI-powered chatbots to help more Chinese cope with mental health issues, amid lack of therapists
Sorry, we couldn’t find any matches for“Alt-protein”.
POPULAR DATABASE
